Accessed 2026-05-27.
A: Gastrointestinal discomfort stands as the dominant adverse response of GLP-1 agonists, including mild nausea, transient vomiting, bloating, diarrhea or constipation, which mostly emerge within the initial 28 weeks of administration as the gastrointestinal tract adapts to delayed emptying effects
Unfortunately, to date, no single drug has been able to fully meet all these stringent criteria (222, 240, 244)
Bull Exp Biol Med 146(5):624626
If discontinuation is appropriate, your provider can help develop an individualized plan
Purpose-built for physicians Preconception GLP-1 receptor agonist use may reduce pregnancy risks Key takeaways: GLP-1 receptor agonist use before pregnancy was tied to lower risks for hypertensive disorders of pregnancy and gestational diabetes